Scott D. Schroeder - Concepedia

Author

Scott D. Schroeder

Gilead Sciences (United States)

Also Known As

S.D. Schroeder, Schroeder, S.D., Scott D Schroeder, Scott D. Schroeder, Scott Schroeder

Publications

695

Citations

H-Index

Concepts

All Affiliations

Gilead Sciences (United States)University of Utah VIR Biotechnology (United States)University of Nebraska–Lincoln

About

Scott D. Schroeder is an author at Gilead Sciences (United States) specializing in hiv, drug discovery, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	600
2	Immunology	4	4	600
3	Natural Sciences	2	2	409
4	Engineering	1	1	17
5	Chemistry	1	1	17

Scott D. Schroeder

Publications

690

Citations

H-Index

Page 1

	Year	Citations
Clinical targeting of HIV capsid protein with a long-acting small molecule John O. Link, Martin S. Rhee, Winston C. Tse, Nature Natural SciencesHuman RetrovirusImmunologyAntiviral TherapyMolecular Biology	2020	392
A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model Stephen R. Yant, Andrew Mulato, Derek Hansen, Nature Medicine MedicineHuman RetrovirusImmunologyAntiviral ResponseAntiviral Drug Development	2019	157
Targeting Methanopterin Biosynthesis ToInhibitMethanogenesis Razvan Dumitru, Hector Palencia, Scott D. Schroeder, Applied and Environmental Microbiology	2003	38
Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral Agent Raju Subramanian, Jennifer Tang, Jim Zheng, Molecular Pharmaceutics Pharmaceutical SciencePharmacokinetic ModelingFlip-flop KineticsMedicineImmunology	2023	38
Controlling Mode Selectivity in Palladium-Catalyzed Bisdiene Carbocyclizations: Optimizing for Cyclization-Trapping over Cycloisomerization James M. Takacs, Scott D. Schroeder, Jianxin Han, Organic Letters	2003	24
Directed Intermolecular Association by Complementary Molecular Edges in 6-Methoxycoumarin Paul W. Baures, J.R. Rush, Scott D. Schroeder, Crystal Growth & Design EngineeringCross-linkNatural SciencesChemical BondCovalent Bonded Framework	2002	17
539. GS-CA2: A Novel, Potent, and Selective First-In-class Inhibitor of HIV-1 Capsid Function Displays Nonclinical Pharmacokinetics Supporting Long-Acting Potential in Humans Jim Zheng, Stephen R. Yant, Shekeba Ahmadyar, Open Forum Infectious Diseases Gs-ca2 Plasma ConcentrationsMedicineHuman RetrovirusImmunologyGs-ca2 Pk Parameters	2018	13
Lenacapavir Exhibits Atropisomerism—Mechanistic Pharmacokinetics and Disposition Studies of Lenacapavir Reveal Intestinal Excretion as a Major Clearance Pathway Jim Zheng, Bing Lu, Gavin Carr, Journal of Pharmacology and Experimental Therapeutics	2024	11

Page 1